Recent developments in peptide-based SPECT radiopharmaceuticals for breast tumor targeting

Life Sciences ◽  
2019 ◽  
Vol 239 ◽  
pp. 116870 ◽  
Author(s):  
Sajjad Ahmadpour ◽  
Seyed Jalal Hosseinimehr
Keyword(s):  
Breast Tumor ◽  
Tumor Targeting ◽  
Recent Developments

Subtle changes in network composition impact the biodistribution and tumor accumulation of nanogels

2018 ◽  
Vol 54 (83) ◽  
pp. 11777-11780 ◽  
Author(s):  
Ilona Zilkowski ◽  
Ioanna Theodorou ◽  
Krystyna Albrecht ◽  
Frederic Ducongé ◽  
Jürgen Groll
Keyword(s):  
Breast Tumor ◽  
Tumor Targeting ◽  
Near Infrared ◽  
Side Chain ◽  
Human Breast ◽  
Human Breast Tumor ◽  
Tumor Xenografts ◽  
Network Composition ◽  
Tumor Accumulation

We studied the effect of subtle changes in side-chain chemistry and labelling with near infrared fluorophores of nanogels (NGs) prepared from thiolated poly(glycidol) on in vivo biodistribution in mice bearing human breast tumor xenografts. Side chain chemistry as well as labelling clearly influenced tumor targeting and overall biodistribution.

Recent advancements in brain tumor targeting using magnetic nanoparticles

2020 ◽  
Vol 11 (2) ◽  
pp. 97-112 ◽  
Author(s):  
Himanshu Gandhi ◽  
Abhishek Kumar Sharma ◽  
Shikha Mahant ◽  
Deepak N Kapoor
Keyword(s):  
Gene Therapy ◽  
Brain Tumor ◽  
Magnetic Nanoparticles ◽  
Biomedical Applications ◽  
Tumor Targeting ◽  
Chemotherapeutic Agents ◽  
Diagnostic Systems ◽  
Hyperthermia Treatment ◽  
Recent Developments ◽  
The Brain

Transport of drugs through the blood–brain barrier to the brain and the toxic effects of drugs on the healthy cells can limit the effectiveness of chemotherapeutic agents. In recent years, magnetic nanoparticles (MNPs) have received much attention as targeted therapeutic and diagnostic systems due to their simplicity, ease of preparation and ability to tailor their properties such as their composition, size, surface morphology, etc. for biomedical applications. MNPs are utilized in drug delivery, radio therapeutics, hyperthermia treatment, gene therapy, biotherapeutics and diagnostic imaging. The present review will address the challenges in brain tumor targeting and discuss the application and recent developments in brain tumor targeting using MNPs.

Breast Tumor Targeting with PAMAM-PEG-5FU-99mTc As a New Therapeutic Nanocomplex: In In-vitro and In-vivo studies

2020 ◽  
Vol 22 (2) ◽  
Author(s):  
Asghar Narmani ◽  
Monire Alsadat Afzali Arani ◽  
Javad Mohammadnejad ◽  
Ali Zaman Vaziri ◽  
Sedigheh Solymani ◽  
...  
Keyword(s):  
Breast Tumor ◽  
Tumor Targeting ◽  
In Vivo Studies

scholarly journals Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True

2020 ◽  
Vol 21 (21) ◽  
pp. 8192
Author(s):  
Mattia D’Agostino ◽  
Salvatore Innorcia ◽  
Mario Boccadoro ◽  
Sara Bringhen
Keyword(s):  
Multiple Myeloma ◽  
Monoclonal Antibodies ◽  
Tumor Targeting ◽  
Drug Class ◽  
Immune Cell ◽  
Standard Of Care ◽  
Preclinical Research ◽  
Drug Conjugates ◽  
Tumor Associated Antigen ◽  
Recent Developments

Immunotherapy is increasingly used in the treatment of multiple myeloma (MM). Monoclonal antibodies (mAbs) are safe and effective ways to elicit immunotherapeutic responses. In 2015, daratumumab has become the first mAb approved by the Food and Drug Administration for clinical use in MM and, in the last 5 years, a lot of clinical and preclinical research has been done to optimize the use of this drug class. Currently, mAbs have already become part of standard-of-care combinations for the treatment of relapsed/refractory MM and very soon they will also be used in the frontline setting. The success of simple mAbs (‘naked mAbs’) prompted the development of new types of molecules. Antibody–drug conjugates (ADCs) are tumor-targeting mAbs that release a cytotoxic payload into the tumor cells upon antigen binding in order to destroy them. Bispecific antibodies (BiAbs) are mAbs simultaneously targeting a tumor-associated antigen and an immune cell-associated antigen in order to redirect the immune cell cytotoxicity against the tumor cell. These different constructs produced solid preclinical data and promising clinical data in phase I/II trials. The aim of this review article is to summarize all the recent developments in the field, including data on naked mAbs, ADCs and BiAbs.

scholarly journals Solid Tumor-Targeting Theranostic Polymer Nanoparticle in Nuclear Medicinal Fields

2014 ◽  
Vol 2014 ◽  
pp. 1-12 ◽  
Author(s):  
Akira Makino ◽  
Shunsaku Kimura
Keyword(s):  
Solid Tumor ◽  
Tumor Targeting ◽  
Therapeutic Agents ◽  
Amphiphilic Polymers ◽  
Polymer Nanoparticles ◽  
Imaging Systems ◽  
Therapeutic Drugs ◽  
Self Assembling ◽  
Recent Developments ◽  
Proper Design

Polymer nanoparticles can be prepared by self-assembling of amphiphilic polymers, and various types of molecular assemblies have been reported. In particular, in medicinal fields, utilization of these polymer nanoparticles as carriers for drug delivery system (DDS) has been actively tried, and some nanoparticulate drugs are currently under preclinical evaluations. A radionuclide is an unstable nucleus and decays with emission of radioactive rays, which can be utilized as a tracer in the diagnostic imaging systems of PET and SPECT and also in therapeutic purposes. Since polymer nanoparticles can encapsulate most of diagnostic and therapeutic agents with a proper design of amphiphilic polymers, they should be effective DDS carriers of radionuclides in the nuclear medicinal field. Indeed, nanoparticles have been recently attracting much attention as common platform carriers for diagnostic and therapeutic drugs and contribute to the development of nanotheranostics. In this paper, recent developments of solid tumor-targeting polymer nanoparticles in nuclear medicinal fields are reviewed.

Breast tumor targeting with 99mTc-HYNIC-PR81 complex as a new biologic radiopharmaceutical

2008 ◽  
Vol 35 (7) ◽  
pp. 763-768 ◽  
Author(s):  
Mojtaba Salouti ◽  
Hossein Rajabi ◽  
Mohammad Hossein Babaei ◽  
Mohammad Javad Rasaee
Keyword(s):  
Breast Tumor ◽  
Tumor Targeting

99mTc-(tricine)-HYNIC-Lys-FROP Peptide for Breast Tumor Targeting

2019 ◽  
Vol 18 (9) ◽  
pp. 1295-1302 ◽  
Author(s):  
Sajjad Ahmadpour ◽  
Zohreh Noaparast ◽  
Seyed Mohammad Abedi ◽  
Seyed Jalal Hosseinimehr
Keyword(s):  
Breast Cancer ◽  
Cell Lines ◽  
Breast Tumor ◽  
Tumor Targeting ◽  
Specific Binding ◽  
Breast Cancer Cell Lines ◽  
Tumor Uptake ◽  
Diagnose Breast Cancer ◽  
Tumor Bearing ◽  
Mcf 7

Background: Breast cancer is a malignant disease with high mortality rate among women in the world. It is necessary to diagnose breast cancer at the early stage before it metastasizes in patients. Objective: The aim of this study is the evaluation of 99mTc-(tricine)-HYNIC-Lys-FROP for breast tumor imaging. Method: Lys-FROP peptide was labeled with 99mTc using HYNIC as chelator and tricine as co-ligand. Specific binding of this radiolabeled peptide on breast cancerous cell was assessed in different cell lines as well as in tumor-bearing mice. Results: HYNIC-Lys-FROP peptide was labeled with 99mTc at radiochemical purity more than 99%. It was observed high stability in normal saline and serum about 95%. The highest cellular uptake was observed in MCF-7 breast tumor cells treated with 99mTc-(tricine)-HYNIC-Lys-FROP as compared to other cell lines (lung, ovarian, T47D breast cancer cell lines). Biodistribution results in female MCF-7 tumor-bearing mice showed the relatively high tumor uptake and tumor-muscle ratio as 3.82 ± 0.66 after 15 min post-injection of 99mTc-(tricine)- HYNIC-Lys-FROP. Tumor uptake was reduced in mice that were co-injected with excess of unlabeled peptide to be 0.91 ± 0.08. Conclusion: Findings showed this radiolabeled peptide is a promising candidate for tumor targeting and molecular imaging of breast cancer.

scholarly journals 99mTc-HYNIC-(tricine/EDDA)-FROP peptide for MCF-7 breast tumor targeting and imaging

2018 ◽  
Vol 25 (1) ◽  
Author(s):  
Sajjad Ahmadpour ◽  
Zohreh Noaparast ◽  
Seyed Mohammad Abedi ◽  
Seyed Jalal Hosseinimehr
Keyword(s):  
Breast Tumor ◽  
Tumor Targeting ◽  
Mcf 7
Sign in / Sign up

Export Citation Format

Share Document